Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

Elias Jabbour, Hagop Kantarjian, Susan O'Brien, Jenny Shan, Guillermo Garcia-Manero, William Wierda, Farhad Ravandi, Gautam Borthakur, Mary Beth Rios, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

We assessed the predictive factors for outcome and response in 123 patients with chronic myeloid leukemia in chronic phase treated with second-generation tyrosine kinase inhibitors (TKIs) after imatinib failure. Better event-free survival rates with second-generation TKI therapy were associated with a previous cytogenetic response to imatinib (P < .001) and a performance status of 0 (P = .001). Patients with 0, 1, or 2 adverse factors had 2-year event-free survival rates of 78%, 49%, and 20% (P < .001), respectively; 2-year overall survival rates of 95%, 85%, and 40%, (P = .002), respectively; and a 12-month probability of achieving a major cytogenetic response of 64%, 36%, and 20% (P = .007), respectively. In conclusion, patients with poor performance status and no previous cytogenetic response to imatinib therapy have a low likelihood of responding to second-generation TKI with poor event-free survival and therefore should be offered additional treatment options. This scoring system could serve to advise patients of their prognosis and treatment options, as well as to evaluate the benefit of newer alternate options.

Original languageEnglish (US)
Pages (from-to)1822-1827
Number of pages6
JournalBlood
Volume117
Issue number6
DOIs
StatePublished - Feb 10 2011
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Protein-Tyrosine Kinases
Cytogenetics
Disease-Free Survival
Survival Rate
Therapeutics
Imatinib Mesylate

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. / Jabbour, Elias; Kantarjian, Hagop; O'Brien, Susan; Shan, Jenny; Garcia-Manero, Guillermo; Wierda, William; Ravandi, Farhad; Borthakur, Gautam; Rios, Mary Beth; Cortes, Jorge.

In: Blood, Vol. 117, No. 6, 10.02.2011, p. 1822-1827.

Research output: Contribution to journalArticle

Jabbour, Elias ; Kantarjian, Hagop ; O'Brien, Susan ; Shan, Jenny ; Garcia-Manero, Guillermo ; Wierda, William ; Ravandi, Farhad ; Borthakur, Gautam ; Rios, Mary Beth ; Cortes, Jorge. / Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. In: Blood. 2011 ; Vol. 117, No. 6. pp. 1822-1827.
@article{635130c4c840499889a073ad922b85e3,
title = "Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure",
abstract = "We assessed the predictive factors for outcome and response in 123 patients with chronic myeloid leukemia in chronic phase treated with second-generation tyrosine kinase inhibitors (TKIs) after imatinib failure. Better event-free survival rates with second-generation TKI therapy were associated with a previous cytogenetic response to imatinib (P < .001) and a performance status of 0 (P = .001). Patients with 0, 1, or 2 adverse factors had 2-year event-free survival rates of 78{\%}, 49{\%}, and 20{\%} (P < .001), respectively; 2-year overall survival rates of 95{\%}, 85{\%}, and 40{\%}, (P = .002), respectively; and a 12-month probability of achieving a major cytogenetic response of 64{\%}, 36{\%}, and 20{\%} (P = .007), respectively. In conclusion, patients with poor performance status and no previous cytogenetic response to imatinib therapy have a low likelihood of responding to second-generation TKI with poor event-free survival and therefore should be offered additional treatment options. This scoring system could serve to advise patients of their prognosis and treatment options, as well as to evaluate the benefit of newer alternate options.",
author = "Elias Jabbour and Hagop Kantarjian and Susan O'Brien and Jenny Shan and Guillermo Garcia-Manero and William Wierda and Farhad Ravandi and Gautam Borthakur and Rios, {Mary Beth} and Jorge Cortes",
year = "2011",
month = "2",
day = "10",
doi = "10.1182/blood-2010-07-293977",
language = "English (US)",
volume = "117",
pages = "1822--1827",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

AU - Jabbour, Elias

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Shan, Jenny

AU - Garcia-Manero, Guillermo

AU - Wierda, William

AU - Ravandi, Farhad

AU - Borthakur, Gautam

AU - Rios, Mary Beth

AU - Cortes, Jorge

PY - 2011/2/10

Y1 - 2011/2/10

N2 - We assessed the predictive factors for outcome and response in 123 patients with chronic myeloid leukemia in chronic phase treated with second-generation tyrosine kinase inhibitors (TKIs) after imatinib failure. Better event-free survival rates with second-generation TKI therapy were associated with a previous cytogenetic response to imatinib (P < .001) and a performance status of 0 (P = .001). Patients with 0, 1, or 2 adverse factors had 2-year event-free survival rates of 78%, 49%, and 20% (P < .001), respectively; 2-year overall survival rates of 95%, 85%, and 40%, (P = .002), respectively; and a 12-month probability of achieving a major cytogenetic response of 64%, 36%, and 20% (P = .007), respectively. In conclusion, patients with poor performance status and no previous cytogenetic response to imatinib therapy have a low likelihood of responding to second-generation TKI with poor event-free survival and therefore should be offered additional treatment options. This scoring system could serve to advise patients of their prognosis and treatment options, as well as to evaluate the benefit of newer alternate options.

AB - We assessed the predictive factors for outcome and response in 123 patients with chronic myeloid leukemia in chronic phase treated with second-generation tyrosine kinase inhibitors (TKIs) after imatinib failure. Better event-free survival rates with second-generation TKI therapy were associated with a previous cytogenetic response to imatinib (P < .001) and a performance status of 0 (P = .001). Patients with 0, 1, or 2 adverse factors had 2-year event-free survival rates of 78%, 49%, and 20% (P < .001), respectively; 2-year overall survival rates of 95%, 85%, and 40%, (P = .002), respectively; and a 12-month probability of achieving a major cytogenetic response of 64%, 36%, and 20% (P = .007), respectively. In conclusion, patients with poor performance status and no previous cytogenetic response to imatinib therapy have a low likelihood of responding to second-generation TKI with poor event-free survival and therefore should be offered additional treatment options. This scoring system could serve to advise patients of their prognosis and treatment options, as well as to evaluate the benefit of newer alternate options.

UR - http://www.scopus.com/inward/record.url?scp=79951477784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951477784&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-07-293977

DO - 10.1182/blood-2010-07-293977

M3 - Article

C2 - 21030554

AN - SCOPUS:79951477784

VL - 117

SP - 1822

EP - 1827

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -